Log in

NASDAQ:PRNBPrincipia Biopharma Stock Price, Forecast & News

$91.89
+4.65 (+5.33 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$88.24
Now: $91.89
$95.15
50-Day Range
$56.00
MA: $71.06
$90.07
52-Week Range
$25.35
Now: $91.89
$95.15
Volume533,173 shs
Average Volume715,862 shs
Market Capitalization$3.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.8
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
Read More
Principia Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.00 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRNB
CUSIPN/A
CIKN/A
Phone650-416-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$35.16 million
Book Value$10.95 per share

Profitability

Net Income$-53,790,000.00

Miscellaneous

Employees65
Market Cap$3.04 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$91.89
+4.65 (+5.33 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRNB News and Ratings via Email

Sign-up to receive the latest news and ratings for PRNB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Principia Biopharma (NASDAQ:PRNB) Frequently Asked Questions

How has Principia Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Principia Biopharma's stock was trading at $53.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PRNB shares have increased by 70.5% and is now trading at $91.89.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Principia Biopharma?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Principia Biopharma in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Principia Biopharma
.

When is Principia Biopharma's next earnings date?

Principia Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Principia Biopharma
.

How were Principia Biopharma's earnings last quarter?

Principia Biopharma Inc (NASDAQ:PRNB) announced its quarterly earnings data on Thursday, August, 6th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of ($1.03) by $1.34.
View Principia Biopharma's earnings history
.

What price target have analysts set for PRNB?

7 Wall Street analysts have issued 1 year price targets for Principia Biopharma's stock. Their forecasts range from $76.00 to $108.00. On average, they anticipate Principia Biopharma's stock price to reach $87.33 in the next year. This suggests that the stock has a possible downside of 5.0%.
View analysts' price targets for Principia Biopharma
.

Has Principia Biopharma been receiving favorable news coverage?

Media headlines about PRNB stock have been trending extremely negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Principia Biopharma earned a daily sentiment score of -4.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Principia Biopharma
.

Who are some of Principia Biopharma's key competitors?

What other stocks do shareholders of Principia Biopharma own?

Who are Principia Biopharma's key executives?

Principia Biopharma's management team includes the following people:
  • Dr. Alan B. Colowick Ph.D., M.D., M.P.H., Exec. Chairman (Age 57)
  • Mr. Martin Babler, CEO & Director (Age 54)
  • Mr. Christopher Y. Chai, Chief Financial Officer (Age 52)
  • Ms. Stefani A. Wolff, Chief Devel. Officer (Age 57)
  • Dr. David M. Goldstein, Chief Scientific Officer (Age 53)

When did Principia Biopharma IPO?

(PRNB) raised $75 million in an initial public offering on Friday, September 14th 2018. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

What is Principia Biopharma's stock symbol?

Principia Biopharma trades on the NASDAQ under the ticker symbol "PRNB."

Who are Principia Biopharma's major shareholders?

Principia Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include First Trust Advisors LP (0.18%), Swiss National Bank (0.17%), Alps Advisors Inc. (0.14%), Candriam Luxembourg S.C.A. (0.13%), New York State Common Retirement Fund (0.08%) and Russell Investments Group Ltd. (0.07%). Company insiders that own Principia Biopharma stock include Alan Colowick, Christopher Y Chai, Daniel J Becker, David Goldstein, David M Goldstein, Dolca Thomas, Leaf Ventures Ii LP New, Martin Babler, Orbimed Advisors Llc, Plc Glaxosmithkline, Roy C Hardiman, Simeon George, Srinivas Akkaraju and Stefani Wolff.
View institutional ownership trends for Principia Biopharma
.

Which major investors are selling Principia Biopharma stock?

PRNB stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Alps Advisors Inc., Candriam Luxembourg S.C.A., Virtus ETF Advisers LLC, SG Americas Securities LLC, and Strs Ohio. Company insiders that have sold Principia Biopharma company stock in the last year include Alan Colowick, Christopher Y Chai, David Goldstein, David M Goldstein, Dolca Thomas, Leaf Ventures Ii LP New, Martin Babler, Roy C Hardiman, and Stefani Wolff.
View insider buying and selling activity for Principia Biopharma
.

Which major investors are buying Principia Biopharma stock?

PRNB stock was purchased by a variety of institutional investors in the last quarter, including Trexquant Investment LP, Rafferty Asset Management LLC, New York State Common Retirement Fund, Swiss National Bank, Principal Financial Group Inc., Russell Investments Group Ltd., Public Employees Retirement Association of Colorado, and State Board of Administration of Florida Retirement System. Company insiders that have bought Principia Biopharma stock in the last two years include Daniel J Becker, Leaf Ventures Ii LP New, Plc Glaxosmithkline, Simeon George, and Srinivas Akkaraju.
View insider buying and selling activity for Principia Biopharma
.

How do I buy shares of Principia Biopharma?

Shares of PRNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Principia Biopharma's stock price today?

One share of PRNB stock can currently be purchased for approximately $91.89.

How big of a company is Principia Biopharma?

Principia Biopharma has a market capitalization of $3.04 billion and generates $35.16 million in revenue each year. The company earns $-53,790,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Principia Biopharma employs 65 workers across the globe.

What is Principia Biopharma's official website?

The official website for Principia Biopharma is www.principiabio.com.

How can I contact Principia Biopharma?

Principia Biopharma's mailing address is 220 East Grand Avenue, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-416-7700 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.